The FDA approved daratumumab and hyaluronidase-fihj for adults with newly diagnosed or relapsed/refractory multiple myeloma. The approval of this product allows for subcutaneous dosing of daratumumab ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN ...
Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Alteogen expects Tergase ® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages. Compared with other commercially available hyaluronidase ...
A naturally occurring enzyme called hyaluronidase may be an effective alternative treatment for spasticity, or muscle stiffness, a disabling condition in people who have had a stroke or other brain ...
Hyaluronan accumulation in tumour stroma is associated with reduced survival in preclinical cancer models. PEGPH20 degrades hyaluronan to facilitate tumour access for cancer therapies. Our objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback